References
- Barbui T, Thiele J, Gisslinger H, et al. Masked polycythemia Vera (mPV): results of an international study. Am J Hematol. 2014;89:52–54.
- Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood. 2007;110:1092–1097.
- Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–2405.
- Ancochea A, Alvarez-Larran A, Morales-Indiano C, et al. The role of serum erythropoietin level and JAK2 V617F allele burden in the diagnosis of polycythaemia vera. Br J Haematol. 2014;167:411–417.
- Lippert E, Boissinot M, Kralovics R, et al. The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera. Blood J. 2006;108:1865–1867.
- Silver RT, Chow W, Orazi A, et al. Evaluation of WHO criteria for diagnosis of polycythemia vera: a prospective analysis. Blood J. 2013;122:1881–1886.
- Laboratory Testing Information-Erythropoietin [Internet]. RSS 20 In Focus. ARUP Laboratories, Web. 28 Feb. 2013. Available from: http://www.aruplab.com/guides/ug/tests/0050227.jsp